Stock AnalizIradimed Corp. IRMD
Medical/Dental Instruments · IPO 2014 · data as of November 13, 2026
Iradimed Corp. (IRMD) is a healthcare company listed in the US with a market value of about $1.1B. In the twelve months to September 30, 2026 it had revenue of $89M and net income of $24M, a net margin of 26.8%.
Its overall Stock Analiz score is 3.8 out of 5 (good). The strongest part is track record (5/5); the weakest is value (1/5).
Key numbers: a P/E of 45.6, a price to free cash flow of 41.8, 5-year revenue growth of 21% a year, a 5-year average ROIC of 18%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 49% below the current price.
Score: 3.8 / 5
Checks passed
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
- 5-year average ROIC above 12%
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- Strong R&D investment or growth above 20%
- Share count down over 3 years (buybacks)
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $89M | $84M | $73M | $66M | $53M | $42M | $32M | $39M | $30M | $23M | $32M |
| Net income | $24M | $22M | $19M | $17M | $13M | $9M | $1M | $10M | $6M | $499764 | $7M |
| Free cash flow | $26M | $17M | $18M | $6M | $9M | $11M | $5M | $10M | $7M | $3M | $9M |
| EPS (diluted) | $1.87 | $1.75 | $1.50 | $1.35 | $1.02 | $0.74 | $0.11 | $0.78 | $0.52 | $0.04 | $0.60 |
| Net margin | 26.8% | 26.8% | 26.3% | 26.2% | 24.1% | 22.3% | 4.3% | 25.0% | 20.7% | 2.2% | 22.2% |
| ROIC | — | 21.9% | 20.0% | 21.6% | 16.2% | 12.5% | -0.9% | 11.7% | 11.3% | 3.1% | 22.6% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 2 analysts is $118.00, 38% above the current price; targets range from $116.00 to $120.00; the consensus rating is “Buy”; expected EPS is $2.10 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Iradimed’s P/E ratio?
About 45.6, based on the last twelve months of diluted earnings per share (forward P/E about 35.7).
Is Iradimed stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 49% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Iradimed pay a dividend?
Yes. The dividend yield is about 0.92%, and it has paid dividends for 4 years in our data.
Is Iradimed a good stock to buy?
We do not give buy or sell advice. Iradimed scores 3.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.